Format

Send to

Choose Destination
Cancer Lett. 2008 Sep 8;268(1):10-30. doi: 10.1016/j.canlet.2008.03.024. Epub 2008 Apr 25.

Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer.

Author information

1
Department of Pharmaceutical and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, 770 Sumter Street, Coker Life Sciences, Room 513C, Columbia, SC 29208, USA. hofseth@cop.sc.edu

Abstract

Nitric oxide (NO) and associated reactive nitrogen species (RNS) are involved in many physiological functions. There has been an ongoing debate to whether RNS can inhibit or perpetuate chronic inflammation and associated carcinogenesis. Although the final outcome depends on the genetic make-up of its target, the surrounding microenvironment, the activity and localization of nitric oxide synthase (NOS) isoforms, and overall levels of NO/RNS, evidence is accumulating that in general, RNS drive inflammation and cancers associated with inflammation. To this end, many complementary and alternative medicines (CAMs) that work in chemoprevention associated with chronic inflammation, are inhibitors of excessive NO observed in inflammatory conditions. Here, we review recent literature outlining a role of NO/RNS in chronic inflammation and cancer, and point toward NO as one of several targets for the success of CAMs in treating chronic inflammation and cancer associated with this inflammation.

PMID:
18440130
PMCID:
PMC2680023
DOI:
10.1016/j.canlet.2008.03.024
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center